Monitoring antiosteoporotic treatment of postmenopausal women using biochemical markers of bone turnover

Drugs of Today

Volumn 35, Issue 3, 1999, Pages 181-185

  Kress, Barry C ^a   Mizrahi, Isaac A ^a  

^a Hybritech Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; ESTROGEN;

BONE DENSITY; BONE MINERAL; BONE TURNOVER; FEMALE; FOLLOW UP; HORMONE SUBSTITUTION; HUMAN; OSTEOLYSIS; OSTEOPOROSIS; PATIENT COMPLIANCE; POSTMENOPAUSE; REVIEW; RISK ASSESSMENT; RISK FACTOR; TURNOVER TIME;

EID: 0032964428     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.1999.35.3.533847     Document Type: Review

References (15)

1. NIH Consensus Development Conference. Diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 1993, 94: 646-50.
2. National Osteoporosis Foundation Development Report. Osteoporosis: Review of the evidence for prevention, diagnosis and treatment and cost-effective analysis. Osteoporosis Int 1998, 8(Suppl. 4): 26-49.
3. Leonard, W.G., Doble, HP. On the efficacy of a compliance pact in reversing osteoporosis h postmenopausal women. Am J Gynecol Health 1990, 4: 112-8.
4. Faulkner, D., Lucy, L.M., Heath, H., Minshal , M., Muchmore, D. A claims data assessment of patient compliance with alendronate. Osteoporosis Int 1998, 8 (Suppl. 3): Abst P021.
5. Melton, L.J., Chrischilles, E.A., Cooper, C. et al. How many women have osteoporosis? J Bone Miner Res 1992, 7: 1005-10.
6. Ray, N.F., Chan, J.K., Thaemer, M., Melton, L.J. III. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1994. J Bone Miner Res 1997, 12: 24-35.
7. Kleerekoper, M. Biochemical markers of bone remodeling. Am J Med Sci 1996, 312: 270-7.
8. Garnero, P., Shih, W.J., Gineyts, E., Karpf, D.B., Delmas, P.D. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 1994, 79: 1693-700.
9. Greenspan, S.L., Parker, R.A., Ferguson, L., Rosen, H., Maitland-Ramsey, L., Karpf, D. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: A randomized clinical trial. J Bone Miner Res 1998, 13: 1431-8.
10. World Congress on Osteoporosis Consensus Committee. Who are candidates for prevention and treatment for osteoporosis? Osteoporosis Int 1997, 7: 1-6.
11. Ravn, P., Christensen, J.O., Baumann, M., Clemmesen, B. Changes in biochemical markers and bone mass after withdrawal of ibandronate treatment: Prediction of bone mass changes during treatment. Bone 1998, 22: 559-64.
12. Rosen, H.N., Moses, A.C., Garber, J., Ross, D.S., Lee, S.L., Greenspan, S.L. Utility of biochemical markers of bone turnover in the follow-up of patients treated with bisphosphonates. Calcif Tissue Int 1998, 63: 363-8.
13. Garnero, P., Sornay-Rendu, E., Delmas, P.D. Long-term variability of markers (mk) of bone turnover: Implications for their diagnostic utility. Osteoporosis Int 1996, 6(Suppl. 1): Abst 190.
14. Davis, J.W., Ross, P.D., Wasnich, R.D., MacLean, C.J., Vogel, J.M. Long-term precision of bone loss rate measurements among postmenopausal women. Calcif Tissue Int 1991, 48: 311-8.
15. Riggs, B.L. Melton, L.J. III, O'Fallon, W.M. Drug therapy for vertebral fractures in osteoporosis: Evidence that decreases in bone turnover and increases in bone mass both determine antifracture efficacy. Bone 1996, 18(Suppl.): 197-201S.